David Wetherell
Founder & Managing Director @ Biomark Capital
San Francisco, United States
David Wetherell is a seed investor at Biomark Capital in San Francisco focused on E-Commerce and Marketplace. David Wetherell - Founder & Managing Director @ Biomark Capital
- Total investments:
- 7
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries David Wetherell invests in
Stages David Wetherell invests in
Countries David Wetherell invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- E-Commerce 1 (14%)
- Marketplace 1 (14%)
- Venture Capital 1 (14%)
- Natural Resources 1 (14%)
Stage
- Seed 2 (29%)
- Funding Round 2 (29%)
- Series B 1 (14%)
- Series E 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| WhiteGlove Health has become a leader in the healthcare industry through providing an extraordinary healthcare experience for members and providing significant cost savings for health plans through reduced insurance claims and reductions in unnecessary utilization. Their comprehensive healthcare strategy is to provide the highest quality care at apredictable cost through highly-skilled nurse practitioners supported by registered nurses in collaboration with physicians, hospitals, other health care providers and carriers.Since 2007, WhiteGlove Health’s highly trained and experienced clinical team comprised of board-certified Nurse Practitioners and Registered Nurses have been making house calls, office calls and providing telephonic support to help members feel better, faster. Their initial focus as a mobile healthcare provider for acute needs and managing chronic conditions has paved the way for the successful introduction of their Value-Based Care division in 2014 which leverages their clinical expertise and ability to deliver provider care to high risk/high cost patients for their Medicare and Medicaid health plan customers. Value-Based Care is conducted at-home or at a Skilled Nursing Facility (SNF) and allows health plans the ability to care for their most challenging patients.Their Solution offers care designed to reduce hospital admissions, re-admissions and prevent unnecessary visits to an emergency room. A WhiteGlove Health Nurse Practitioner has the ability to order or discontinue medications, add home health or durable medical Equipment (as needed) and routinely communicate with the Primary Care Physician on behalf of the patient. The WhiteGlove Health strategy of prompt follow-up and proactive intervention allows us to carefully monitor patients and manage utilization.In June 2014, WhiteGlove Health acquired Glenridge Healthcare Solutions, a leading consulting, technology and professional services firm, founded in 1997 and headquartered in Maryland. Together, their companies are creating more opportunities and efficiencies than they could have achieved independently. Glenridge continues to partner with customers nationwide by providing a seasoned team, advanced data analytic capabilities and state-of-the art technology to their established impressive portfolio. | $12.9M / Series E / Apr 12, 2012 | ||
| HyperMed is developing hyperspectral imaging for medical applications. The technology, originally developed for military surveillance, provides an advanced form of spectroscopy that provides a two-dimensional tissue oxygenation map. The company’s first product, OxyVu, was developed for the US research market and subsequently received FDA 510(k)approval for medical diagnostic applications where the measurement of microvasculature perfusion can assist physicians with patient care. Multiple published studies have demonstrated the clinical utility of OxyVu for the diagnostic assessment of wound healing, diabetic foot ulcers, and amputation planning. The market opportunity for the clinical diagnostic applications for hyperspectral imaging represent a multi-billion market. | Jan 02, 2012 | ||
| Lentigen Corporation, a biotechnology company, engages in the development and commercialization of gene delivery technologies for human disease. It provides lentiviral vector technology for a range of therapeutic, vaccine, and research applications in biotechnology and medicine. The company offers LG690, a cell therapy for treatment of graft vs hotdiseases; LG768, a cancer vaccine for the treatment of leukemia; stem cell therapy to prevent and treat medical disorders; LG631, a treatment that makes chemotheraphy for brain cancer less toxic; LG889, a steam cell therapy for hemophilia; LG611, an exact strain matched influenza vaccine for pandemic flu; LG811, an exact strain matched influenza vaccine for seasonal flu; LG747, a biosimilar erytho poieitin; and LG888, a novel factor VIII protein therapy for Hemophilia A. Lentigen Corporation was founded in 2004 and is headquartered in Gaithersburg, Maryland. | Jan 02, 2012 | ||
| iStart Ventures is a venture capital firm specializing in early stage investments. It provides Internet start-up ventures with core business systems, a complete set of resources, and an infusion of initial seed funding. | $4M / Series B / Apr 26, 2000 | ||
| PaperExchange.comSM is a leading global e-commerce marketplace for the pulp and paper industry with more than 4,500 corporate members and over 6,500 individual members, spread out over more than 80 countries. PaperExchange.com's members have completed transactions in all major grades of paper, and have made PaperExchange.com one of theworld's most frequented sites in the pulp and paper industry. Not only has the Company shown consistent and rapid growth in terms of bidding activity, completed transactions, tons of product posted, and number of registered members, but the Company's site activity, as measured by user sessions, reached dramatically higher new all-time records in each consecutive quarter of 1999. PaperExchange.com is open for business 24 hours a day, seven days a week. The Company is located in the central Back Bay area of Boston, Massachusetts, USA. | $10M / Seed / Jan 13, 2000 | ||
| iStart Ventures is a venture capital firm specializing in early stage investments. It provides Internet start-up ventures with core business systems, a complete set of resources, and an infusion of initial seed funding. | $2.3M / Seed / Sep 01, 1999 | ||
| See all 7 investments → | |||
Co-Investors
About Biomark Capital
Biomark Capital provides venture funding and assistance to early, mid, and late-stage life science companies. We target companies with novel approaches to diagnostics, therapeutics, medical devices, and digital health that will change the face of healthcare innovation in the future. We share the drive and vision of our portfolio companies tocollaborate with them in accelerating growth and building successful business ventures.
Biomark Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anna G. Annenko
Director
|
|||
Bryant E. Fong
Managing Director
|
|||
|
David Wetherell
Founder & Managing Director
|
|||
Douglas Lind
Managing Director
|
|||
Janos Redei
EIR
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does David Wetherell invest in?
David Wetherell invests primarily in E-Commerce, Marketplace and Venture Capital startups, most often at Seed and Funding Round stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact David Wetherell?
Public channels for David Wetherell include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did David Wetherell last invest?
The most recent investment recorded for David Wetherell closed in Apr 2012. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
